A Helpful Suite of Clinical Resources for Your Practice

Access clinical tools for use with patients as well as multimedia resources providing information on diagnosis of irritable bowel syndrome with diarrhea (IBS-D) and treatment of IBS-D in adults with XIFAXAN.

Clinical Tools

IBS-D Treatment Symptom Questionnaire for Nurse Practitioners (NPs) and Physician Assistants (PAs)

IBS-D Symptom Questionnaire

A guide for patients to assess their symptoms of abdominal pain and diarrhea. Share with your patients prior to or during their visit to help facilitate a more productive discussion about their symptoms.

Download PDF >
IBS-D Treatment Patient Discussion Guide

IBS-D Patient Discussion Guide

Encourages patients to have a discussion with their healthcare provider about their bowel habits using the Bristol Stool Form Scale. Have your patients complete the simple discussion questions to aid in discussions and symptom-based diagnosis of IBS-D.

Download PDF >

Educational Resources

Nurse Practitioner Perspective Treating Adults with IBS-D Video

NP Perspective: Treating Adult Patients With IBS-D

Watch Christina J. Hanson, FNP, discuss her clinical experience in treating patients with IBS-D and what it’s like for patients to live with IBS-D symptoms.

Watch video >
Role Gut Microbiota May Play in the Etiology of IBS-D Video

Expert Discussion: Role Gut Microbiota May Play in the Etiology of IBS-D

Discussion from experts Mark Pimentel, MD, and Darren Brenner, MD, on the importance of gut microbiota for regulating physiologic processes and maintaining health and how perturbations have been associated with several diseases, including IBS-D. Watch to learn how bacterial imbalances may occur and how they may be associated with the pathophysiology of IBS-D in some patients.1-9

Watch video >
Managing IBS-D Symptoms Video

Expert Discussion: Managing IBS-D Symptoms

Discussion from experts Mark Pimentel, MD, and Darren Brenner, MD, on nonpharmacologic and pharmacologic interventions to help manage IBS-D symptoms. Includes a discussion from Joscelyn Greaves, NP, and one of her patients on the challenges of living with IBS-D.

Watch video >
Pathophysiology of IBS-D and Mechanism of Action of XIFAXAN Video

Expert Discussion: Pathophysiology of IBS-D and Mechanism of Action of XIFAXAN

Discussion from expert Mark Pimentel, MD, on the complex pathophysiology of IBS-D and the mechanism of action of XIFAXAN.

Watch video >

Clinical Tools

XIFAXAN IBS-D Treatment Dosing Guide for Nurse Practitioners (NPs) and Physician Assistants (PAs)

XIFAXAN Dosing for IBS-D

Review the recommended dosing for IBS-D in adults and for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. Refer to this dual-indication card for general XIFAXAN dosing – includes the ICD-10 code* for IBS-D.

Download PDF >
XIFAXAN IBS-D Treatment Patient Brochure for Nurse Practitioners (NPs) and Physician Assistants (PAs)

XIFAXAN Patient Brochure

Informational brochure for patients that provides an overview of IBS-D and treatment with XIFAXAN, including how XIFAXAN works, how to take XIFAXAN, efficacy, safety, and most common side effects. Provide this brochure to patients to help them understand treatment with XIFAXAN.

Download PDF >
XIFAXAN Prior Authorization Road Map

XIFAXAN Prior Authorization Road Map

Step-by-step guide for completing prior authorization (PA) requirements for patients prescribed XIFAXAN, including common reasons for PA denials and guidance for Letters of Medical Necessity when needed. Download for guidance on PA requests, as well as information on electronic submissions with CoverMyMeds.

Download PDF >
XIFAXAN Treatment Savings Card

XIFAXAN
Savings Card

Most eligible patients with commercial insurance and coverage for XIFAXAN may pay as little as $0 for their XIFAXAN prescription. Maximum benefits and other restrictions apply.

Get savings card >

Educational Resources

XIFAXAN Product Details

XIFAXAN Product Details

Core information on XIFAXAN for the treatment of IBS-D in adults and for the reduction in risk of overt hepatic encephalopathy recurrence in adults. Provides an overview of symptom-based diagnosis of IBS-D, pathophysiology, and core efficacy and safety data for XIFAXAN, as well as information on insurance coverage. Obtain core product details about XIFAXAN in one informational brochure.

Download PDF >
Treating IBS-D With XIFAXAN Video

Expert Discussion: Treating IBS-D With XIFAXAN

Discussion from experts Mark Pimentel, MD, and Darren Brenner, MD, on the efficacy and safety of XIFAXAN in clinical trials. Includes a discussion from Joscelyn Greaves, NP, and one of her patients on how XIFAXAN was able to help manage her IBS-D. Learn how XIFAXAN may be able to help your adult patients with IBS-D and how to appropriately set expectations prior to treatment.

Watch video >
Efficacy and Safety of XIFAXAN Video

Expert Review: Efficacy and Safety of XIFAXAN

Presentation by expert Mark Pimentel, MD, on the efficacy and safety of XIFAXAN in clinical trials. Review key data supporting the use of XIFAXAN for your adult patients with IBS-D.

Watch video >
XIFAXAN Treatment Savings Card

Help your eligible patients save on XIFAXAN.

$0 copay for most eligible, commercially insured patients with coverage for XIFAXAN. Maximum benefits and other restrictions apply.

Get Savings Card

Request Samples of XIFAXAN for IBS-D

*The ICD-10 Codes and all other patient-access-related information are provided for informational purposes only. It is the treating physician’s responsibility to determine the proper diagnosis, treatment and applicable ICD-10 Code. Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.

American Academy of Physician Assistants (AAPA)
Visit website >
American Association of Nurse Practitioners (AANP)
Visit website >
American College of Gastroenterology (ACG) Advanced Practice Providers Resource Center

Visit website >

Access ACG's online IBS Screener for patients >

American Gastroenterological Association (AGA) NP/PA Resource Center
Visit website >
Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
Visit website >
Society of Gastroenterology Nurses and Associates (SGNA)
Visit website >
World Gastroenterology Organisation (WGO)
Visit website >
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN were:
    • HE (≥10%): Peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

References: 1. Uribe A, Alam M, Johansson O, Midtvedt T, Theodorsson E. Microflora modulates endocrine cells in the gastrointestinal mucosa of the rat. Gastroenterology. 1994;107(5):1259-1269. 2. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107-118. 3. Corr SC, Li Y, Riedel CU, O’Toole PW, Hill C, Gahan CGM. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A. 2007;104(18):7617-7621. 4. Cherbuy C, Darcy-Vrillon B, Morel MT, Pégorier JP, Duée PH. Effect of germfree state on the capacities of isolated rat colonocytes to metabolize n-butyrate, glucose, and glutamine. Gastroenterology. 1995;109(6):1890-1899. 5. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5(7):e177. 6. Biedermann L, Brülisauer K, Zeitz J, et al. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. Inflamm Bowel Dis. 2014;20(9):1496-1501. 7. Chen Z, Hui PC, Hui M, et al. Impact of preservation method and 16S rRNA hypervariable region on gut microbiota profiling. mSystems. 2019;4(1):e00271-18. 8. Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G799-G807. 9. Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012;24(6):521-e248.

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.